TherapeuticsMD, Inc. (TXMD)
2.21
-0.03
(-1.34%)
USD |
NASDAQ |
Sep 04, 16:00
2.17
-0.04
(-1.81%)
After-Hours: 20:00
TherapeuticsMD Enterprise Value : 21.95M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 21.95M |
| September 03, 2026 | 22.30M |
| September 02, 2026 | 22.53M |
| September 01, 2026 | 21.49M |
| August 31, 2026 | 21.60M |
| August 28, 2026 | 22.07M |
| August 27, 2026 | 22.07M |
| August 26, 2026 | 22.76M |
| August 25, 2026 | 22.76M |
| August 24, 2026 | 20.33M |
| August 21, 2026 | 20.21M |
| August 20, 2026 | 20.21M |
| August 19, 2026 | 19.87M |
| August 18, 2026 | 19.63M |
| August 17, 2026 | 19.63M |
| August 14, 2026 | 20.33M |
| August 13, 2026 | 20.44M |
| August 12, 2026 | 20.44M |
| August 11, 2026 | 20.33M |
| August 10, 2026 | 20.33M |
| August 07, 2026 | 20.33M |
| August 06, 2026 | 20.56M |
| August 05, 2026 | 20.33M |
| August 04, 2026 | 19.98M |
| August 03, 2026 | 19.98M |
| Date | Value |
|---|---|
| July 31, 2026 | 19.87M |
| July 30, 2026 | 19.87M |
| July 29, 2026 | 20.21M |
| July 28, 2026 | 20.21M |
| July 27, 2026 | 20.33M |
| July 24, 2026 | 20.21M |
| July 23, 2026 | 20.21M |
| July 22, 2026 | 19.75M |
| July 21, 2026 | 19.98M |
| July 20, 2026 | 20.79M |
| July 17, 2026 | 20.21M |
| July 16, 2026 | 19.98M |
| July 15, 2026 | 18.82M |
| July 14, 2026 | 19.17M |
| July 13, 2026 | 19.17M |
| July 10, 2026 | 19.52M |
| July 09, 2026 | 19.63M |
| July 08, 2026 | 19.17M |
| July 07, 2026 | 19.17M |
| July 06, 2026 | 19.17M |
| July 02, 2026 | 20.79M |
| July 01, 2026 | 21.37M |
| June 30, 2026 | 21.95M |
| June 29, 2026 | 23.34M |
| June 26, 2026 | 21.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.871B |
| Corcept Therapeutics, Inc. | 11.75B |
| Veru, Inc. | 21.90M |
| Johnson & Johnson | 691.09B |
| Eli Lilly & Co. | 1.128T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.164M |
| Revenue (Quarterly) | 0.869M |
| Total Expenses (Quarterly) | 0.705M |
| EPS Diluted (Quarterly) | 0.0133 |
| Gross Profit Margin (Quarterly) | 62.14% |
| Profit Margin (Quarterly) | 18.87% |
| Earnings Yield | -0.86% |
| Normalized Earnings Yield | -0.5792 |